Clinical Pharmacology MedUni Vienna’s Post

At the European Renal Association #ERA24 congress taking place this week, newly published data are shedding light on the importance of following guideline-directed medical therapy in cardiorenal patients with hyperkalaemia (HK).     We know that HK is manageable, and hospitalisations are avoidable when treated as a chronic condition. However, patients with HK often see their renin‐angiotensin‐aldosterone system inhibitor (RAASi) medications reduced or even stopped, resulting in an increase in hospitalisations.       HK should not be a barrier to optimised care. We must work together to drive a deeper understanding of how to manage this condition in the long term.    Find out more here: https://lnkd.in/ddpYG6jF

Many patients who present to the ED for acute bleeding are on oral #anticoagulant therapy, including DOACs1, which increases morbidity and mortality compared to those who are not. It is critically important to understand the extent to which a patient is anticoagulated, or not, when determining if reversal or replacement therapy is warranted. For #healthcareprofessionals, rapid acquisition of actionable data is a must for making decisions with confidence. The Perosphere ClotChek is a novel, DOAC-sensitive, point-of-care diagnostic device that is newly available in the EU, which enables healthcare professionals to have a holistic view of a patient’s coagulation status within 3-8 minutes. Learn more about the Perosphere ClotChek, our #pointofcare #coagulometer that is CE Marked in the EU: https://lnkd.in/eyM-idsD Source: Budnitz DS, et al. US Emergency Department Visits Attributed to Medication Harms, 2017-2019. JAMA. doi:10.1001/jama.2021.13844

In this webinar, Dr. Ashley Bourgeois will thoroughly review pyoderma, including which cases may benefit from systemic antimicrobial treatment and which may benefit from topical therapy and alternative treatments such as photobiomodulation. #thedermvet Thanks, Dr. Ashley Bourgeois clinician's brief | vetoquinol.

The latest supplement reviews the Inari LimFlow transcatheter arterialization of deep veins (TADV) system for no-option CLTI patients. Articles cover clinical trial data, best practices for use, cost considerations, & more. | #Sponsored by LimFlow SA

Did you know that Critical Care at Fresenius Medical Care includes 🔹 acute blood purification, 🔹 heart and lung support & 🔹 therapeutic apheresis? Together we are shaping the future of multi-organ support ➡️ http://ow.ly/X91g50LJwZe

A new study shows that #finerenone, a medication for chronic kidney disease sold under the brand name Kerendia®(finerenone) HCP™ in the U.S., can significantly reduce the risk of worsening heart failure and cardiovascular death in specific patients. This offers a promising new treatment option for millions living with heart failure, particularly those with mildly reduced or preserved ejection fraction. The study, published in the New England Journal of Medicine (NEJM Group), underscores the need for continued research and innovation in this area. In order to receive FDA approval for use in these people with heart failure, Bayer, would need to apply to the agency for an expanded indication. Click here to read more: https://lnkd.in/egRf6uDm Read the study publication here: https://lnkd.in/edPKn6aB Find the clinical evidence for #Kerendia at DRUGDOCS® here: https://lnkd.in/eSjfwgBq

The Elliot Lewis Center team presented preliminary late breaking data at CMSC comparing premedication regimens for Ocrevus. The research found patients on Ocrevus receiving a combination of oral cetirizine, dexamethasone, and famotidine had a similar frequency and severity of treatment related symptoms, but less sedation than patients receiving oral diphenhydramine, intravenous dexamethasone, and oral famotidine. The data showed this can be a safe and effective premedication regimen for patients with multiple sclerosis pursuing ocrelizumab. https://lnkd.in/eEnc4q9T

Chronic hand eczema (CHE) is a debilitating dermatosis with limited approved therapies. Learn more here about how to assess and manage patients with CHE: http://ms.spr.ly/6043mmVqP

New treatment alert for #multipleSclerosis patients 🔔‼️ The FDA had approved #Ocrelizumab and Hyaluronidase ( Ocrevus Zunovo) a Twice yearly #subcutaneous injection for Relapsing MS AND primary progressive MS. That would bring the first and only twice a year 10 minutes subcutaneous injection for people living with RMS and PPMS👏 That’s a huge milestone in treatment advancement and innovation in clinical research programs to broaden the scientific understanding of MS , further reducing disability progression in RMS and PPMS and improving the treatment experience for those living with the disease. 🙏🤝 #MSInnovation #TheMSPharmacist #MultipleSclerosis #BeatMS

New data to help in treatment decisions for Crohn's disease patients! A study recently published in the New England Journal of Medicine shows that risankizumab, brand name SKYRIZI® is more effective than ustekinumab, brand name STELARA® in achieving clinical and endoscopic remission in patients with moderate-to-severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or an inadequate response to such therapy. Significant strides in treatment options! Find the clinical evidence for both #SKYRIZI & #STELARA on DRUGDOCS® Read the paper here: https://lnkd.in/ex5znVzp #CrohnsDisease #MedicalResearch #IBD